Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review

Despite an anticipated price tag of $2.5 million, there's no way to predict who will have long-standing benefit from valoctocogene roxaparvovec and who will not.

Related Keywords

South Africa ,United States ,Johannesburg ,Gauteng ,Philadelphia ,Pennsylvania ,Lindsey George ,Johnny Mahlangu ,Pfizer ,Biomarin Pharmaceuticals ,Drug Administration ,Novo Nordisk ,University Of The Witwatersrand ,New England Journal ,Asklepios Biopharmaceutical ,Hemophilia ,Blood ,Factor Viii ,Hemophilia A ,Biologic Therapy ,Genomics ,Genomic Medicine ,Edicine Genomic ,Gene Therapy ,Prophylaxis ,Hemophilia B ,Aminotransferase ,Dust ,Liver Enzymes ,Liver Studies ,Olt ,Liver ,Intravenous Iv ,Intravenous ,Tv ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Europe ,European ,Factor X ,Lotting Factor X ,Stuart Prower Factor ,Hrombokinase ,Hemorrhage ,Bleeding ,Hospitals ,